Physician profile
Evan N Berman
NPI 1528013679
$9,917.10
in general payments reported to CMS, 2019-2025
19 companies · $634 in 2025
The $634 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $282 · 2020: $94.72 · 2021: $119 · 2022: $571 · 2023: $2,750 · 2024: $5,465 · 2025: $634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $3,500 · Travel and Lodging: $2,661 · Food and Beverage: $1,888 · Consulting Fee: $800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $3,500.00 |
| Travel and Lodging | $2,661.47 |
| Food and Beverage | $1,888.34 |
| Consulting Fee | $800.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,928.36 | 2023-2025 | Davinci Xi, Da Vinci Surgical System |
| Solventum Corporation | $1,101.36 | 2024-2025 | 3m Ioban, Ioban 2, Prevena |
| Becton, Dickinson and Company | $450.00 | 2022 | |
| Smith+Nephew, INC. | $292.06 | 2019-2025 | Grafix Pl, Oasis |
| Kci USA, INC. | $231.64 | 2019-2023 | Abthera Advance |
| Organogenesis INC. | $196.45 | 2025 | Apligraf, Affinity, Cygnus Matrix |
| Tela Bio, INC. | $135.20 | 2019 | |
| Janssen Pharmaceuticals, INC | $132.38 | 2019-2023 | Xarelto |
| Abbvie INC. | $126.57 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $54.00 | 2020 | |
| Medtronic, INC. | $47.73 | 2023 | V-Loc 180 |
| Integra Lifesciences Corporation | $45.01 | 2025 | Tcc-Ez |
| Pfizer INC. | $41.71 | 2021 | |
| Davol INC. | $37.87 | 2024-2025 | Phasix Mesh |
| Next Science LLC | $24.73 | 2024 | Surgx, Xperience, Blastx |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Reddress USA, INC. | $21.85 | 2024 | |
| Nevro Corp. | $21.82 | 2019 | |
| Paratek Pharmaceuticals, INC. | $16.11 | 2023 | Nuzyra |
| Mallinckrodt Enterprises LLC | $12.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evan Berman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.